Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05947825

Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients

PDAC - Pancreatic Ductal Adenocarcinoma Clinical Trial

Official title:
The Safety and Tolerance of Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in Subjects With Locally Advanced and Metastatic Pancreatic Adenocarcinoma: an Open, One-Armed, Single-Center, Phase Ⅱ Study.

Clinical Trial Summary

The purpose of this study is to determine the safety and tolerance of sitagliptin combined with gemcitabine and albumin-bound paclitaxel in subjects with locally advanced and metastatic pancreatic ductal adenocarcinoma.

Clinical Trial Description

This is a single-institution, prospective, open, one-armed phase Ⅱ clinical trial of sitagliptin combined with gemcitabine and nab-paclitaxel. This study will enroll 30 PDAC patients over 12-15 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05947825
Study type Interventional
Source Tianjin Medical University Cancer Institute and Hospital
Contact Jihui Hao, Dr.
Phone 86-022-23340123
Email haojihui@tjmuch.com
Status Not yet recruiting
Phase Phase 2
Start date July 30, 2023
Completion date August 1, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05642962 - Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) Phase 1/Phase 2
Recruiting NCT06122896 - Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals Early Phase 1
Recruiting NCT05262855 - Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma Phase 2
Recruiting NCT04700488 - Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC) N/A
Recruiting NCT06151223 - A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
Recruiting NCT05845801 - Prospective Registry of Young-Adult Patients Diagnosed With Pancreatic Cancer
Recruiting NCT05853198 - Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of Resectability N/A
Recruiting NCT05669287 - Defining a Vascular Phenotype of Pancreatic Ductal Adenocarcinoma With CT Perfusion Using Quantitative Radiomics N/A
Recruiting NCT05727020 - Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma
Recruiting NCT05218889 - Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT05132244 - Monitoring and Managing Glucose Levels in People With Pancreatic Cancer N/A
Recruiting NCT04365049 - Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma